ClinicalTrials.gg
Active, not recruitingNCT05161169Updated Oct 2, 2026

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants

An interventional study of Genome Sequencing in Genetic Predisposition to Disease and Hereditary Diseases, sponsored by Brigham and Women's Hospital. Active, not recruiting at 3 sites in United States. Open to participants aged 0 Months to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Screening

How we know

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
640
Allocation
Randomized
Ages
0 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Enrollment
14th of 37
640 · median 225
Started
2022
with 4 others
No phase
30 of 87
8 open now
Primary completion
2027-04
later than 12 of 45 live
Registered
56th of 87
by date
Lead sponsor
6 of 87
Brigham and Women's Hospital

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 14th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 with no phase, reaches primary completion later than 12 of the 45 other live ones, and was the 56th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 0 Months to 12 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of over 500 healthy infants and their parents from Boston, MA; New York City, NY; Birmingham, AL; and additional U.S. cities. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings.

Read the detailed description

The objective of this research protocol is to assess the impacts of genomic sequencing in healthy infants from ethnically and racially diverse communities as part of routine pediatric care.

Investigators will enroll a cohort of over 500 healthy, ethnically and racially diverse infants from Boston, Massachusetts; New York City, New York; Birmingham, Alabama, and other U.S. cities and recruitment sites. As part of this study, a stakeholder board comprised of diverse community members will provide early and regular feedback throughout the study on anticipated and ongoing community reaction to the work with sensitivity to historical injustices and cultural diversity

Primary care pediatricians from each recruitment site will be enrolled for a brief genomics education curriculum. Only infants whose healthcare providers have joined the study will be enrolled.

A small blood sample will be obtained from each enrolled infant. Participants will randomized (1:1) to receive either a family history report or a family history report plus whole genome sequencing.

Genome sequencing data will be analyzed for pathogenic and likely pathogenic variants in genes associated with childhood-onset disease risks, as well as highly actionable adult-onset disease risks. If infants have a dominant risk identified, parents may choose to be screened as part of the study.

The study team will disclose the infant's randomization status and study results during a consultation with each family, and results will be sent to the infant's pediatrician.

Parents will be surveyed at three time points over the 12 months after enrollment: baseline, immediately post-disclosure (approximately 3 months after enrollment), and 6 months post-disclosure. Surveys will assess psychosocial impacts of newborn sequencing.

Chart reviews will be performed 12 months post-disclosure to assess the medical outcomes and healthcare utilization costs of newborn genome sequencing.

03

Conditions studied

  • Genetic Predisposition to Disease
  • Hereditary Diseases

Keywords

  • genome sequencing
  • newborn screening
  • preventive medicine
04

Who can participate

Ages eligible
0 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infant participants

  • Has not previously had exome or genome sequencing
  • Age 0-12 months
  • Seen for well-baby pediatric care at a recruiting site
  • Primary healthcare provider completed the genomics education program
  • At least one parent or guardian able to participate in the study

Parent participants

  • Biological parent or legal guardian of an infant participating in the study
  • 18 years of age or older
  • Unimpaired decision-making capacity
  • English or Spanish speaking
  • Available to have genetic counseling and provide consent for testing the infant

Exclusion criteria

Exclusion Criteria:

  • Parents are unwilling to have genomic reports placed in the medical record or sent to their primary care pediatrician
  • Any infant in which clinical considerations preclude collecting blood via heel stick
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
640 participants (actual)

Study arms

  • Experimental
    Sequencing cohort

    Infants receive genome sequencing with analysis of 4,299 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.

    Genetic: Genome Sequencing

  • No intervention
    Control cohort

    Infants receive a detailed family history report plus standard well-child care.

Interventions

  • GeneticGenome Sequencing

    20 times read depth (20x) next-generation whole genome sequencing with comprehensive analysis.

06

What researchers measure

Primary outcomes

  1. Monogenic disease risks (MDRs)

    Pathogenic (P) and likely pathogenic (LP) variants identified relevant to infant's health (dominant or biallelic recessive disease risks)

    Time frame: 3 months after enrollment

  2. Carrier status variants

    P and LP variants identified as recessive carrier status in infant

    Time frame: 3 months after enrollment

  3. MDR-associated phenotype

    Signs or symptoms of monogenic disease risk identified by genome sequencing

    Time frame: 3 months after enrollment and 1-year post-disclosure (15 months after enrollment)

  4. Parenting stress, relationship dysfunction

    Parenting Stress Index, 4th Edition Short Form (scored as a percentile 0 - 100%, higher scores indicate increased stress)

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  5. Relationship satisfaction

    Kansas Marital Satisfaction Scale (Scored 3 to 21, higher scores indicate better marital quality)

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  6. General anxiety

    General Anxiety Disorder-7

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

Secondary outcomes

  1. MDR-associated family history

    Signs or symptoms of monogenic disease risk or recessive condition present in infant's biological family

    Time frame: 3 months after enrollment and 1-year post-disclosure (15 months after enrollment)

  2. Intervention prompted by genetic or family history report

    Healthcare intervention prompted by MDR or recessive carrier variant

    Time frame: 6 months post-disclosure (9 months after enrollment)

  3. Suspected genetic condition

    Any phenotype that develops in an infant or a family history suspected to have a genetic cause

    Time frame: 6 months post-disclosure (9 months after enrollment)

  4. Child vulnerability

    Vulnerable Baby Scale (scored 0-50, higher scores indicate increased perceptions of child vulnerability)

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  5. Feelings about genomic testing

    Feelings About genomiC Testing Results (FACToR) Questionnaire

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  6. Partner blame

    Novel item (higher scores indicate increased blame)

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  7. General depression

    Patient Health Questionnaire (PHQ)-8

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

  8. Self blame

    Novel item (higher scores indicate increased blame)

    Time frame: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)

Other outcomes

  1. Cost of attributable services

    Cost of health care services associated with surveillance and diagnosis of GS and family history risks

    Time frame: 6 months post-disclosure (9 months after enrollment)

  2. Cost of genomic services

    Cost of genetic services infants and parents received after study disclosure session

    Time frame: 6 months post-disclosure (9 months after enrollment)

  3. All healthcare costs

    All health sector costs observed in medical records and survey questions regarding family out-of-pocket expenses

    Time frame: 6 months post-disclosure (9 months after enrollment)

07

Study locations

3 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The study protocol and statistical analysis plan will be shared on clinical trials.gov

Supporting information: Study protocol, Statistical analysis plan

Time frame: Supporting information will be shared 6 months after study completion.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.

Of 57 non-industry interventional studies with no phase under Genetic Predisposition to Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 128. This study's planned 52 months is above that.

Counting every sponsor, half of 57 studies reached it within 36 months; a quarter within 18 and three quarters within 128.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jun 2025 → Apr 2027 and completion Jun 2025 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Dec 17, 2021
StartActual
Dec 21, 2022
Primary completionEst.
Apr 2027was Jun 2025
CompletionEst.
Oct 2027was Jun 2025
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Active, not recruiting
changed Oct 2, 2026
Sites
1 site removed
Show 1 removed
  • Beaumont - Corewell Health East · Royal Oak, United States
Oct 2, 2026
Primary completion
Jun 30, 2025→Apr 2027
Oct 2, 2026
Study completion
Jun 30, 2025→Oct 2027
Oct 2, 2026
Enrollment
500→640
Oct 2, 2026
Sponsor
Collaborators removed: Dartmouth-Hitchcock Medical Center·Howard University
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Completed→Active, not recruiting
    1 site removed
    Show 1 removed
    • Beaumont - Corewell Health East · Royal Oak, United States
    Primary completion Jun 30, 2025→Apr 2027
    Study completion Jun 30, 2025→Oct 2027
    Enrollment 500→640
    Sponsor Collaborators removed: Dartmouth-Hitchcock Medical Center·Howard University
    + 5 other changes: verification date, description, arm descriptions, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05161169
Responsible party
Robert C. Green, MD, MPH (Professor of Medicine (Genetics), Brigham and Women's Hospital) — Principal investigator
First posted
Dec 17, 2021
Start date
Dec 21, 2022
Primary completion
Apr 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Robert C. Green, MD, MPH
principal investigator · Brigham and Women's Hospital
Ingrid A. Holm, MD, MPH
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion